Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stock
Anthem Biosciences Limited specializes in manufacturing specialty organic molecules and biologically active peptides, catering primarily to the drug and specialty chemicals industries.
The company reported a decline in quarterly revenue, with Q3FY26 showing a 15% year-over-year decrease compared to Q3FY25, while maintaining robust EBITDA margins around 41.8%.
Despite revenue challenges, Anthem focused on margin improvement, achieving an EBITDA growth of 22.6% for 9MFY26 compared to 9MFY25.
The strategic emphasis on backward integration and cost control is evident, as shown by a reduction in material costs, thus improving overall profitability.
Anthem's expanding scope into biosimilars and the strong performance of its CRDMO segment highlight its dedication to innovative biotech solutions.
Pharmaceuticals & Biotechnology
Biotechnology
44,566 Cr
Low Risk
75.3
34.6
2.1
14.7
873.25
579.45
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
789.10 | 44,566 Cr | 75.31 | 14.65 | 0.25 | 19.45 | 26.70 | 17.26 | ||
1585.20 | 40,189 Cr | 35.22 | 4.98 | 0.38 | 14.15 | 18.58 | 9.63 | ||
2332.85 | 39,520 Cr | 38.15 | 17.43 | 2.44 | 45.69 | 61.23 | 23.96 | ||
3079.65 | 38,263 Cr | 36.23 | 8.45 | 0.92 | 23.33 | 29.09 | 17.16 | ||
2196.50 | 36,258 Cr | 35.29 | 3.50 | 0.91 | 9.92 | 14.02 | 8.21 | ||
2191.65 | 35,151 Cr | 49.55 | 8.45 | 1.01 | 17.06 | 22.99 | 14.28 | ||
1782.00 | 33,647 Cr | 36.40 | 6.80 | 0.20 | 18.67 | 21.76 | 9.79 | ||
| Median: 7 Co. | — | 2191.65 | 38,263 Cr | 36.40 | 8.45 | 0.91 | 18.67 | 22.99 | 14.28 |
Anthem Biosciences Ltd (ANTHEM) is currently trading at 766.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Anthem Biosciences Limited specializes in manufacturing specialty organic molecules and biologically active peptides, catering primarily to the drug and specialty chemicals industries. The company reported a decline in quarterly revenue, with Q3FY26 showing a 15% year-over-year decrease compared to Q3FY25, while maintaining robust EBITDA margins around 41.8%. Despite revenue challenges, Anthem focused on margin improvement, achieving an EBITDA growth of 22.6% for 9MFY26 compared to 9MFY25. The strategic emphasis on backward integration and cost control is evident, as shown by a reduction in material costs, thus improving overall profitability. Anthem's expanding scope into biosimilars and the strong performance of its CRDMO segment highlight its dedication to innovative biotech solutions.
Over the past 52 weeks, Anthem Biosciences Ltd has traded between a low of ₹579.45 and a high of ₹873.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Anthem Biosciences Ltd has a market capitalization of approximately 44,565.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Anthem Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 75.31 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 44,565.63 Cr, Anthem Biosciences Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Anthem Biosciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Anthem Biosciences Ltd is 75.31. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investors bought 1,71,14,604 shares, representing a 3.05% stake, at an average price of ₹744.80 per share.
Promoter Aruna Ganesh sold 1,71,14,604 shares, representing a 3.05% stake, and exited the company.
The key announcement is the 'Biopharma Shakti' initiative, a program with a ₹10,000 crore outlay over five years to develop India as a global hub for biopharmaceutical manufacturing, focusing on biologics and biosimilars.
Bearish
0
Neutral
8
Bullish
6
Bearish
19
Neutral
8
Bullish
19
Bearish
19
Neutral
0
Bullish
13
Promoter share sale
Aruna Ganesh, a member of the promoter group of Anthem Biosciences Ltd, sold her entire holding of 1,71,14,604 equity shares (3.05% of share capital) and filed disclosure under Reg.29(2) of SEBI (SAST) Regulations, 2011.
Promoter share sale
Aruna Ganesh (promoter group) disclosed sale of entire 1,71,14,604 equity shares (3.05% of equity) in Anthem Biosciences under Reg.29(2) of SEBI SAST; buyer/consideration not specified and promoter-group status unchanged.
